Scott C Bresler

Dr. Scott C Bresler

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2021 in The Oncologist
Verified
Journal Article
Open access
PDF file
AKAlon Kahana
Alon Kahana
SUShelby P. Unsworth
Shelby P. Unsworth
CAChristopher A. Andrews
Christopher A. Andrews
MCMay P. Chan
May P. Chan
SBScott C Bresler
Scott C Bresler
FWFrancis P. Worden
Francis P. Worden
Background: Basal cell carcinoma (BCC) is a common skin cancer often curable by excision; however, for patients with BCC around the eye, excision places visual organs and function at risk. In this article, we test the hypothesis that use of the hedgehog inhibitor vismodegib will improve vision-related outcomes in patients with orbital and extensive periocular BCC (opBCC). Materials and Methods: In this open-label, nonrandomized phase IV trial, we enrolled patients with globe- and lacrimal drainage system–threatening opBCC. To assess visual function in the context of invasive periorbital and lacrimal disease, we used a novel Visual Assessment Weighted Score (VAWS) in addition to standard ophthalmic exams. Primary endpoint was VAWS with a score of 21/50 (or greater) considered successful, signifying globe preservation. Tumor response was evaluated using RECIST v1.1. Surgical specimens were examined histologically by dermatopathologists. Results: In 34 patients with opBCC, mean VAWS was 44/50 at baseline, 46/50 at 3 months, and 47/50 at 12 months or postsurgery. In total, 100% of patients maintained successful VAWS outcome at study endpoint. Compared with baseline, 3% (95% confidence interval [CI], 0.1–15.3) experienced major score decline (5+ points), 14.7% (95% CI, 5 to 31.1) experienced a minor decline (2–4 points), and 79.4% experienced a stable or improved score (95% CI, 62.1–91.3). A total of 56% (19) of patients demonstrated complete tumor regression by physical examination, and 47% (16) had complete regression by MRI/CT. A total of 79.4% (27) of patients underwent surgery, of which 67% (18) had no histologic evidence of disease, 22% (6) had residual disease with clear margins, and 11% (3) had residual disease extending to margins. Conclusion: Vismodegib treatment, primary or neoadjuvant, preserves globe and visual function in patients with opBCC. Clinical trail identification number.NCT02436408. Implications for Practice: Use of the antihedgehog inhibitor vismodegib resulted in preservation of end-organ function, specifically with regard to preservation of the eye and lacrimal apparatus when treating extensive periocular basal cell carcinoma. Vismodegib as a neoadjuvant also maximized clinical benefit while minimizing toxic side effects. This is the first prospective clinical trial to demonstrate efficacy of neoadjuvant antihedgehog therapy for locally advanced periocular basal cell carcinoma, and the first such trial to demonstrate end-organ preservation.

23 June 2021 in Journal of Cutaneous Pathology
Verified
Journal Article
Closed access
PDF file
ASAndrew M. Schuler
Andrew M. Schuler
ESEmily H. Smith
Emily H. Smith
KCKristine M. Chaudet
Kristine M. Chaudet
SBScott C Bresler
Scott C Bresler
JGJohann E. Gudjonsson
Johann E. Gudjonsson
MCMay P. Chan
May P. Chan

5 January 2022 in The American Journal of Dermatopathology
Verified
Journal Article
Closed access
NKNicholas Bs Kline
Nicholas Bs Kline
TMTyler D. Menge
Tyler D. Menge
SHSteven M. Hrycaj
Steven M. Hrycaj
AAAleodor A. Andea
Aleodor A. Andea
RPRajiv M. Patel
Rajiv M. Patel
SBScott C Bresler
Scott C Bresler
Preferentially expressed antigen in melanoma (PRAME) is an immunohistochemical biomarker that is diffusely expressed in most cutaneous melanomas and is negative in most benign nevi. Histologically challenging dermal melanocytic neoplasms, such as cellular blue nevi (CBN) and deep penetrating nevi (DPN), and soft tissue tumors with melanocytic differentiation, such as clear cell sarcoma and perivascular epithelioid cell tumor, may resemble primary or metastatic melanoma. PRAME immunohistochemistry (IHC) was applied to archived formalin-fixed, paraffin-embedded specimens of various dermal melanocytic neoplasms and soft tissue neoplasms with melanocytic differentiation. Staining was graded based on the percentage of melanocytes labeled (0–4+ as previously reported). The gold standard was final pathologic diagnosis using histologic, immunophenotypic, and in some cases molecular findings. Fifty-four cases were evaluated. 62.5% (5/8) of blue nevus-like melanomas and 50% (1/2) of DPN-like melanomas were PRAME positive (4+). Of the other tumors, 100% (20/20) of CBN (including 1 atypical CBN with borderline features); 100% (12/12) of DPN, combined DPN, or borderline DPN; 88.9% (8/9) of perivascular epithelioid cell tumors; and 100% (3/3) of clear cell sarcoma were PRAME negative (0–2+). Within the borderline categories specifically, all 8 tumors (1 borderline CBN and 7 borderline DPN) showed low (0–2+) PRAME expression. Overall, the sensitivity for melanoma in this context was 60%, with a specificity of 97.7%. Although our sample size is limited, the results suggest that IHC staining for PRAME may be useful in supporting a diagnosis of melanoma in the setting of challenging dermal melanocytic neoplasms and other epithelioid neoplasms with melanocytic differentiation. However, PRAME IHC lacks sensitivity in this context.

22 April 2019 in Journal of Cutaneous Pathology
Verified
Journal Article
Closed access
PDF file
JZJoseph Zahn
Joseph Zahn
MCMay P. Chan
May P. Chan
GWGrace Wang
Grace Wang
RPRajiv M. Patel
Rajiv M. Patel
AAAleodor A. Andea
Aleodor A. Andea
PHPaul Harms
Paul Harms

1 April 2020 in JAAD Case Reports
Verified
Journal Article
Open access
MRMason Runge
Mason Runge
KWKiyanna Williams
Kiyanna Williams
TSThomas Scharnitz
Thomas Scharnitz
MNMio Nakamura
Mio Nakamura
MEMilad Eshaq
Milad Eshaq
LLLori Lowe
Lori Lowe

11 July 2022 in Journal of Cutaneous Pathology
Verified
Journal Article
Open access
JPJaclyn Plotzke
Jaclyn Plotzke
NZNicholas A. Zoumberos
Nicholas A. Zoumberos
SHSteven M. Hrycaj
Steven M. Hrycaj
PHPaul Harms
Paul Harms
SBScott C Bresler
Scott C Bresler
MCMay P. Chan
May P. Chan